Growth inhibition of Escherichia coli and methicillin-resistant Staphylococcus aureus by targeting cellular methionine aminopeptidase

Sergio C. Chai, Wen Long Wang, De Rong Ding, Qizhuang Ye

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Methionine aminopeptidase (MetAP) catalyzes the N-terminal methionine excision from the majority of newly synthesized proteins, which is an essential cotranslational process required for cell survival. As such, MetAP has become an appealing target for the development of antimicrobial therapeutics with novel mechanisms of action. By screening a library of small organic molecules, we previously discovered a class of compounds that selectively inhibit the Fe(II)-form of MetAP. Herein, we demonstrate that some of these compounds and their newly synthesized derivatives halt the growth of Escherichia coli and Staphylococcus aureus cells with significant potency. The most potent compound inhibited methicillin-resistant S. aureus (MRSA) growth with an IC50 value of 1 μM and MIC of 0.7 μg/ml. Two cell-based assays were used to verify that MetAP is the intracellular target in E. coli cells. These findings can serve as foundation for the development of novel therapeutics against an ever increasing threat by drug resistant staphylococcal infections.

Original languageEnglish
Pages (from-to)3537-3540
Number of pages4
JournalEuropean Journal of Medicinal Chemistry
Volume46
Issue number8
DOIs
StatePublished - Aug 2011

Fingerprint

Aminopeptidases
Methicillin
Methicillin-Resistant Staphylococcus aureus
Methionine
Escherichia coli
Growth
Small Molecule Libraries
CD13 Antigens
Staphylococcal Infections
Inhibitory Concentration 50
Staphylococcus aureus
Assays
Cell Survival
Screening
Cells
Derivatives
Molecules
Therapeutics
Pharmaceutical Preparations
Proteins

Keywords

  • Antibiotic
  • Drug discovery
  • Drug resistance
  • Enzyme inhibition
  • Hydrolase
  • Metalloenzyme

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Pharmacology

Cite this

Growth inhibition of Escherichia coli and methicillin-resistant Staphylococcus aureus by targeting cellular methionine aminopeptidase. / Chai, Sergio C.; Wang, Wen Long; Ding, De Rong; Ye, Qizhuang.

In: European Journal of Medicinal Chemistry, Vol. 46, No. 8, 08.2011, p. 3537-3540.

Research output: Contribution to journalArticle

@article{cdb30c17f7084ee1a4b4ee032490e818,
title = "Growth inhibition of Escherichia coli and methicillin-resistant Staphylococcus aureus by targeting cellular methionine aminopeptidase",
abstract = "Methionine aminopeptidase (MetAP) catalyzes the N-terminal methionine excision from the majority of newly synthesized proteins, which is an essential cotranslational process required for cell survival. As such, MetAP has become an appealing target for the development of antimicrobial therapeutics with novel mechanisms of action. By screening a library of small organic molecules, we previously discovered a class of compounds that selectively inhibit the Fe(II)-form of MetAP. Herein, we demonstrate that some of these compounds and their newly synthesized derivatives halt the growth of Escherichia coli and Staphylococcus aureus cells with significant potency. The most potent compound inhibited methicillin-resistant S. aureus (MRSA) growth with an IC50 value of 1 μM and MIC of 0.7 μg/ml. Two cell-based assays were used to verify that MetAP is the intracellular target in E. coli cells. These findings can serve as foundation for the development of novel therapeutics against an ever increasing threat by drug resistant staphylococcal infections.",
keywords = "Antibiotic, Drug discovery, Drug resistance, Enzyme inhibition, Hydrolase, Metalloenzyme",
author = "Chai, {Sergio C.} and Wang, {Wen Long} and Ding, {De Rong} and Qizhuang Ye",
year = "2011",
month = "8",
doi = "10.1016/j.ejmech.2011.04.056",
language = "English",
volume = "46",
pages = "3537--3540",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",
number = "8",

}

TY - JOUR

T1 - Growth inhibition of Escherichia coli and methicillin-resistant Staphylococcus aureus by targeting cellular methionine aminopeptidase

AU - Chai, Sergio C.

AU - Wang, Wen Long

AU - Ding, De Rong

AU - Ye, Qizhuang

PY - 2011/8

Y1 - 2011/8

N2 - Methionine aminopeptidase (MetAP) catalyzes the N-terminal methionine excision from the majority of newly synthesized proteins, which is an essential cotranslational process required for cell survival. As such, MetAP has become an appealing target for the development of antimicrobial therapeutics with novel mechanisms of action. By screening a library of small organic molecules, we previously discovered a class of compounds that selectively inhibit the Fe(II)-form of MetAP. Herein, we demonstrate that some of these compounds and their newly synthesized derivatives halt the growth of Escherichia coli and Staphylococcus aureus cells with significant potency. The most potent compound inhibited methicillin-resistant S. aureus (MRSA) growth with an IC50 value of 1 μM and MIC of 0.7 μg/ml. Two cell-based assays were used to verify that MetAP is the intracellular target in E. coli cells. These findings can serve as foundation for the development of novel therapeutics against an ever increasing threat by drug resistant staphylococcal infections.

AB - Methionine aminopeptidase (MetAP) catalyzes the N-terminal methionine excision from the majority of newly synthesized proteins, which is an essential cotranslational process required for cell survival. As such, MetAP has become an appealing target for the development of antimicrobial therapeutics with novel mechanisms of action. By screening a library of small organic molecules, we previously discovered a class of compounds that selectively inhibit the Fe(II)-form of MetAP. Herein, we demonstrate that some of these compounds and their newly synthesized derivatives halt the growth of Escherichia coli and Staphylococcus aureus cells with significant potency. The most potent compound inhibited methicillin-resistant S. aureus (MRSA) growth with an IC50 value of 1 μM and MIC of 0.7 μg/ml. Two cell-based assays were used to verify that MetAP is the intracellular target in E. coli cells. These findings can serve as foundation for the development of novel therapeutics against an ever increasing threat by drug resistant staphylococcal infections.

KW - Antibiotic

KW - Drug discovery

KW - Drug resistance

KW - Enzyme inhibition

KW - Hydrolase

KW - Metalloenzyme

UR - http://www.scopus.com/inward/record.url?scp=79958249114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958249114&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2011.04.056

DO - 10.1016/j.ejmech.2011.04.056

M3 - Article

C2 - 21575996

AN - SCOPUS:79958249114

VL - 46

SP - 3537

EP - 3540

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

IS - 8

ER -